{
    "clinical_study": {
        "@rank": "122579", 
        "arm_group": [
            {
                "arm_group_label": "Reference (Part 1/A, Part 2/C)", 
                "arm_group_type": "Experimental", 
                "description": "multiple doses of dabigatran (alone)"
            }, 
            {
                "arm_group_label": "Test 1 (Part 1/Treatment B)", 
                "arm_group_type": "Experimental", 
                "description": "concomitant administration of dabigatran and ticagrelor"
            }, 
            {
                "arm_group_label": "Test 2 (Part 2/Treatment D)", 
                "arm_group_type": "Experimental", 
                "description": "staggered administration of ticagrelor and dabigatran"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the pharmacokinetic and pharmacodynamic interaction of dabigatran and\n      ticagrelor under steady state conditions; to investigate the effect of staggered\n      administration of ticagrelor loading dose on dabigatran exposure (in Part II)"
        }, 
        "brief_title": "Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "B1", 
                            "description": "In part 1, 110 mg dabigatran etexilate were dosed twice daily to steady state and a dabigatran PK profile was taken on day 3 (reference). On the day after the reference treatment, ticagrelor treatment was added starting with the concomitant administration of a 180 mg ticagrelor loading dose followed by 90 mg ticagrelor twice daily. Dabigatran PK profiles were taken on day 1 of the test treatment and day 4 of the test treatment.", 
                            "title": "Part 1"
                        }, 
                        {
                            "@group_id": "B2", 
                            "description": "In part 2, 110 mg dabigatran etexilate were dosed twice daily to steady state and a dabigatran PK profile was taken on day 3 (reference). On the day after the reference treatment, 180 mg ticagrelor were given 2 hours after the morning dose of 110 mg dabigatran etexilate and dabigatran PK profile were taken on this day 1 of the test treatment.", 
                            "title": "Part 2"
                        }, 
                        {
                            "@group_id": "B3", 
                            "description": "Total of all reporting groups", 
                            "title": "Total"
                        }
                    ]
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "24"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "24"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "48"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@spread": "7.2", 
                                                "@value": "28.0"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@spread": "7.1", 
                                                "@value": "28.6"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@spread": "7.15", 
                                                "@value": "28.3"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "0"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "24"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "24"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "48"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }
                    ]
                }, 
                "population": "Treated Set which includes all subjects who were documented to have received at least 1 dose of trial medication."
            }, 
            "certain_agreements": {
                "pi_employee": "All Principal Investigators ARE employed by the organization sponsoring the study.", 
                "restrictive_agreement": "Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "analysis_list": {
                            "analysis": [
                                {
                                    "ci_lower_limit": "124.388", 
                                    "ci_percent": "90", 
                                    "ci_upper_limit": "179.383", 
                                    "dispersion_type": "Standard Deviation", 
                                    "dispersion_value": "37.6", 
                                    "estimate_desc": "The dispersion value is actually the intraindividual gCV.", 
                                    "group_id_list": {
                                        "group_id": [
                                            "O1", 
                                            "O2"
                                        ]
                                    }, 
                                    "method": "ANOVA", 
                                    "method_desc": "Adjustment for effects 'subject' and 'treatment'.", 
                                    "non_inferiority": "Yes", 
                                    "non_inferiority_desc": "Relative bioavailability", 
                                    "p_value": "0.9456", 
                                    "p_value_desc": "p-value for ratio outside interval 80% - 125%", 
                                    "param_type": "geometric Mean Ratio", 
                                    "param_value": "149.38"
                                }, 
                                {
                                    "ci_lower_limit": "107.363", 
                                    "ci_percent": "90", 
                                    "ci_upper_limit": "148.967", 
                                    "dispersion_type": "Standard Deviation", 
                                    "dispersion_value": "33.3", 
                                    "estimate_desc": "The dispersion value is actually the intraindividual gCV.", 
                                    "group_id_list": {
                                        "group_id": [
                                            "O1", 
                                            "O3"
                                        ]
                                    }, 
                                    "method": "ANOVA", 
                                    "method_desc": "Adjustment for effects 'subject' and 'treatment'.", 
                                    "non_inferiority": "Yes", 
                                    "non_inferiority_desc": "Relative bioavailability", 
                                    "p_value": "0.5481", 
                                    "p_value_desc": "p-value for ratio outside interval 80% - 125%", 
                                    "param_type": "geometric Mean Ratio", 
                                    "param_value": "126.47"
                                }, 
                                {
                                    "ci_lower_limit": "108.047", 
                                    "ci_percent": "90", 
                                    "ci_upper_limit": "149.295", 
                                    "dispersion_type": "Standard Deviation", 
                                    "dispersion_value": "31.6", 
                                    "estimate_desc": "The dispersion value is actually the intraindividual gCV.", 
                                    "group_id_list": {
                                        "group_id": [
                                            "O4", 
                                            "O5"
                                        ]
                                    }, 
                                    "method": "ANOVA", 
                                    "method_desc": "Adjustment for effects 'subject' and 'treatment'.", 
                                    "non_inferiority": "Yes", 
                                    "non_inferiority_desc": "Relative bioavailability", 
                                    "p_value": "0.5665", 
                                    "p_value_desc": "p-value for ratio outside interval 80% - 125%", 
                                    "param_type": "geometric Mean Ratio", 
                                    "param_value": "127.01"
                                }
                            ]
                        }, 
                        "description": "Area under the concentration-time curve of dabigatran etexilate in plasma at steady state over the uniform dosing interval \u03c4 (AUC\u03c4,ss).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Dabigatran Etexilate 110mg twice daily (bid) for 3 days", 
                                    "title": "Dabigratan Etexilate 110mg Bid Alone - Part 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Single loading dose of Ticagrelor 180 mg on day 1  together with  Dabigatran Etexilate 110mg bid.", 
                                    "title": "Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Multiple dosing of 90 mg bid on days 2 and 3 and 90mg on day 4 together with  Dabigatran Etexilate 110mg bid on days 2 and 3 and 110mg in the morning on day 4.", 
                                    "title": "Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1"
                                }, 
                                {
                                    "@group_id": "O4", 
                                    "description": "Dabigatran Etexilate 110mg twice daily (bid) for 3 days", 
                                    "title": "Dabigratan Etexilate 110mg Bid Alone - Part 2"
                                }, 
                                {
                                    "@group_id": "O5", 
                                    "description": "Dabigatran Etexilate 110mg morning dose followed by 180mg Ticagrelor 2 hours later.", 
                                    "title": "Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "24"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "23"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "23"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@value": "23"
                                                    }, 
                                                    {
                                                        "@group_id": "O5", 
                                                        "@value": "21"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "59.0", 
                                                        "@value": "551"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "43.3", 
                                                        "@value": "817"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "55.1", 
                                                        "@value": "689"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@spread": "39.6", 
                                                        "@value": "660"
                                                    }, 
                                                    {
                                                        "@group_id": "O5", 
                                                        "@spread": "43.4", 
                                                        "@value": "844"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Area under the concentration-time curve of dabigatran etexilate in plasma at steady state over the uniform dosing interval \u03c4 (AUC\u03c4,ss).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval \u03c4 (AUC\u03c4,ss)", 
                                    "units": "ng*h/mL"
                                }
                            ]
                        }, 
                        "population": "Pharmacokinetic set: This subject set included all subjects in the TS who provided at least 1 observation for at least 1 PK endpoint without important protocol violations relevant to the evaluation of bioavailability and who had not vomiting at or before 2 times the median tmax,ss of the trial medications on PK study days of both trial parts.", 
                        "safety_issue": "No", 
                        "time_frame": "47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours", 
                        "title": "Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval \u03c4 (AUC\u03c4,ss)", 
                        "type": "Primary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": [
                                {
                                    "ci_lower_limit": "133.945", 
                                    "ci_percent": "90", 
                                    "ci_upper_limit": "202.619", 
                                    "dispersion_type": "Standard Deviation", 
                                    "dispersion_value": "42.9", 
                                    "estimate_desc": "The dispersion value is actually the intraindividual gCV.", 
                                    "group_id_list": {
                                        "group_id": [
                                            "O1", 
                                            "O2"
                                        ]
                                    }, 
                                    "method": "ANOVA", 
                                    "method_desc": "Adjustment for effects 'subject' and 'treatment'.", 
                                    "non_inferiority": "Yes", 
                                    "non_inferiority_desc": "Relative bioavailability", 
                                    "p_value": "0.9841", 
                                    "p_value_desc": "p-value for ratio outside interval 80% - 125%", 
                                    "param_type": "geometric Mean Ratio", 
                                    "param_value": "164.74"
                                }, 
                                {
                                    "ci_lower_limit": "106.370", 
                                    "ci_percent": "90", 
                                    "ci_upper_limit": "155.495", 
                                    "dispersion_type": "Standard Deviation", 
                                    "dispersion_value": "39.0", 
                                    "estimate_desc": "The dispersion value is actually the intraindividual gCV.", 
                                    "group_id_list": {
                                        "group_id": [
                                            "O1", 
                                            "O3"
                                        ]
                                    }, 
                                    "method": "ANOVA", 
                                    "method_desc": "Adjustment for effects 'subject' and 'treatment'.", 
                                    "non_inferiority": "Yes", 
                                    "non_inferiority_desc": "Relative bioavailability", 
                                    "p_value": "0.6003", 
                                    "p_value_desc": "p-value for ratio outside interval 80% - 125%", 
                                    "param_type": "geometric Mean Ratio", 
                                    "param_value": "128.61"
                                }, 
                                {
                                    "ci_lower_limit": "102.695", 
                                    "ci_percent": "90", 
                                    "ci_upper_limit": "149.288", 
                                    "dispersion_type": "Standard Deviation", 
                                    "dispersion_value": "36.9", 
                                    "estimate_desc": "The dispersion value is actually the intraindividual gCV.", 
                                    "group_id_list": {
                                        "group_id": [
                                            "O4", 
                                            "O5"
                                        ]
                                    }, 
                                    "method": "ANOVA", 
                                    "method_desc": "Adjustment for effects 'subject' and 'treatment'.", 
                                    "non_inferiority": "Yes", 
                                    "non_inferiority_desc": "Relative bioavailability", 
                                    "p_value": "0.4656", 
                                    "p_value_desc": "p-value for ratio outside interval 80% - 125%", 
                                    "param_type": "gMean Ratio", 
                                    "param_value": "123.82"
                                }
                            ]
                        }, 
                        "description": "Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Dabigatran Etexilate 110mg twice daily (bid) for 3 days", 
                                    "title": "Dabigratan Etexilate 110mg Bid Alone - Part 1"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Single loading dose of Ticagrelor 180 mg on day 1  together with  Dabigatran Etexilate 110mg bid.", 
                                    "title": "Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Multiple dosing of 90 mg bid on days 2 and 3 and 90mg on day 4 together with  Dabigatran Etexilate 110mg bid on days 2 and 3 and 110mg in the morning on day 4.", 
                                    "title": "Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1"
                                }, 
                                {
                                    "@group_id": "O4", 
                                    "description": "Dabigatran Etexilate 110mg twice daily (bid) for 3 days", 
                                    "title": "Dabigratan Etexilate 110mg Bid Alone - Part 2"
                                }, 
                                {
                                    "@group_id": "O5", 
                                    "description": "Dabigatran Etexilate 110mg morning dose followed by 180mg Ticagrelor 2 hours later.", 
                                    "title": "Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "24"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "23"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "23"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@value": "23"
                                                    }, 
                                                    {
                                                        "@group_id": "O5", 
                                                        "@value": "21"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "69.3", 
                                                        "@value": "83.6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "45.4", 
                                                        "@value": "136"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "65.1", 
                                                        "@value": "106"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@spread": "46.5", 
                                                        "@value": "97.6"
                                                    }, 
                                                    {
                                                        "@group_id": "O5", 
                                                        "@spread": "45.2", 
                                                        "@value": "121"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss)", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Pharmacokinetic set: This subject set included all subjects in the TS who provided at least 1 observation for at least 1 PK endpoint without important protocol violations relevant to the evaluation of bioavailability and who had not vomiting at or before 2 times the median tmax,ss of the trial medications on PK study days of both trial parts.", 
                        "safety_issue": "No", 
                        "time_frame": "47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours", 
                        "title": "Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss)", 
                        "type": "Primary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "P1", 
                            "description": "In part 1, 110 mg dabigatran etexilate were dosed twice daily to steady state and a dabigatran PK profile was taken on day 3 (reference). On the day after the reference treatment, ticagrelor treatment was added starting with the concomitant administration of a 180 mg ticagrelor loading dose followed by 90 mg ticagrelor twice daily. Dabigatran PK profiles were taken on day 1 of the test treatment and day 4  of the test treatment.", 
                            "title": "Part 1"
                        }, 
                        {
                            "@group_id": "P2", 
                            "description": "In part 2, 110 mg dabigatran etexilate were dosed twice daily to steady state and a dabigatran PK profile was taken on day 3 (reference). On the day after the  reference treatment, 180 mg ticagrelor were given 2 hours after the morning dose of 110 mg dabigatran etexilate and dabigatran PK profile were taken on this day 1 of the test treatment.", 
                            "title": "Part 2"
                        }
                    ]
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "1", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "2", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "Adverse Event"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "1", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "Withdrawal by Subject"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "24", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "24", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "23", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "21", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "1", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "3", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "email": "clintriage.rdg@boehringer-ingelheim.com", 
                "name_or_title": "Boehringer Ingelheim Call Center", 
                "organization": "Boehringer Ingelheim Pharmaceuticals", 
                "phone": "1-800-243-0127"
            }, 
            "reported_events": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "E1", 
                            "description": "Dabigatran Etexilate 110mg twice daily (bid) for 3 days", 
                            "title": "Dabigratan Etexilate 110mg Bid Alone - Part 1"
                        }, 
                        {
                            "@group_id": "E2", 
                            "description": "Single loading dose of Ticagrelor 180 mg on day 1  together with  Dabigatran Etexilate 110mg bid.", 
                            "title": "Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1"
                        }, 
                        {
                            "@group_id": "E3", 
                            "description": "Multiple dosing of 90 mg bid on days 2 and 3 and 90mg on day 4 together with  Dabigatran Etexilate 110mg bid on days 2 and 3 and 110mg once on day 4.", 
                            "title": "Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1"
                        }, 
                        {
                            "@group_id": "E4", 
                            "description": "Dabigatran Etexilate 110mg twice daily (bid) for 3 days", 
                            "title": "Dabigratan Etexilate 110mg Bid Alone - Part 2"
                        }, 
                        {
                            "@group_id": "E5", 
                            "description": "Dabigatran Etexilate 110mg morning dose followed by 180mg Ticagrelor 2 hours later.", 
                            "title": "Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2"
                        }
                    ]
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "24"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "23"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "23"
                                            }, 
                                            {
                                                "@group_id": "E4", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "24"
                                            }, 
                                            {
                                                "@group_id": "E5", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "21"
                                            }
                                        ], 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "24"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "23"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "23"
                                            }, 
                                            {
                                                "@group_id": "E4", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "24"
                                            }, 
                                            {
                                                "@group_id": "E5", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "21"
                                            }
                                        ], 
                                        "sub_title": "Headache"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "MEDDRA 16.0", 
                    "frequency_threshold": "5"
                }, 
                "time_frame": "11 days"
            }
        }, 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. Healthy male subjects.\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2012", 
        "firstreceived_results_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01734772", 
            "org_study_id": "1160.142", 
            "secondary_id": "2012-002656-16"
        }, 
        "intervention": [
            {
                "arm_group_label": "Test 1 (Part 1/Treatment B)", 
                "description": "multiple doses of dabigatran", 
                "intervention_name": "dabigatran etexilate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference (Part 1/A, Part 2/C)", 
                "description": "medium dose dabigatran", 
                "intervention_name": "dabigatran etexilate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test 1 (Part 1/Treatment B)", 
                "description": "loading dose of ticagrelor", 
                "intervention_name": "ticagrelor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test 1 (Part 1/Treatment B)", 
                "description": "multiple doses of ticagrelor", 
                "intervention_name": "ticagrelor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test 2 (Part 2/Treatment D)", 
                "description": "loading dose of ticagrelor", 
                "intervention_name": "ticagrelor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test 2 (Part 2/Treatment D)", 
                "description": "single dose of dabigatran", 
                "intervention_name": "dabigatran etexilate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ticagrelor"
        }, 
        "lastchanged_date": "April 2, 2014", 
        "link": {
            "url": "http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1160/1160.142_U13-2049-01.pdf"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1160.142.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor Under Steady State Conditions in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the concentration-time curve of dabigatran etexilate in plasma at steady state over the uniform dosing interval \u03c4 (AUC\u03c4,ss).", 
                "measure": "Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval \u03c4 (AUC\u03c4,ss)", 
                "safety_issue": "No", 
                "time_frame": "47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours"
            }, 
            {
                "description": "Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss).", 
                "measure": "Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01734772"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}